T.R. Jeffry Evans

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

Hepatology, Medicine, Randomised Phase 3 +11

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Colin W. Steele, Saadia A. Karim, Joshua D.G. Leach et al. · Cancer Cell · 2016 · 819 citations · Full text

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

Jennifer P. Morton, Paul Timpson, Saadia A. Karim et al. · Proceedings of the National Academy of Sciences · 2009 · 673 citations · Full text

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans et al. · Journal of Clinical Oncology · 2014 · 572 citations · Full text

Targeting the <scp>LOX</scp> / <scp>hypoxia</scp> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <scp>LOX</scp> abrogates metastasis and enhances drug efficacy

Bryan W. Miller, Jennifer P. Morton, Mark Pinese et al. · EMBO Molecular Medicine · 2015 · 259 citations · Full text

Tumor Biology, Oncology, Pancreatic Cancer +14